Understanding how CD38 affects NAD metabolism in scleroderma
Official title: CD38 modulation of NAD metabolism driving scleroderma pathogenesis
Funded at University of Michigan at Ann Arbor · NIH-10913581 · Data updated 2026-11-12
This study is looking at how a protein called CD38 affects a substance in the body that helps with energy and may play a role in the development of scleroderma, a condition that causes hardening and damage to organs, and it aims to find new treatment options by working with patient samples and animal models.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $648,599 |
| NIH project number | 5R01AR081788-02 |
| Project ID | NIH-10913581 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic sclerosis (scleroderma) who are experiencing fibrosis-related complications.
✕Less likely to help
Patients with other forms of fibrosis not related to scleroderma may not benefit from this research.
What this research studies
This research investigates the role of CD38 and its impact on NAD metabolism in the development of scleroderma, a condition that causes fibrosis and damage to multiple organs. The study aims to explore how dysregulation of NAD and nicotinamide metabolism contributes to the disease's progression. By examining patient biopsies and using animal models, the researchers will assess the potential of targeting CD38 and related enzymes as a new therapeutic approach. Patients may be involved in providing biopsies or participating in related clinical assessments.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target the underlying mechanisms of scleroderma, potentially improving patient outcomes.
How similar studies have gone: While the approach of targeting NAD metabolism in scleroderma is novel, preliminary findings suggest that similar strategies have shown promise in other fibrotic conditions.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Varga, John — University of Michigan at Ann Arbor
- Study coordinator: Varga, John
Related research
Other NIH-funded projects on the same topics.
-
Angiogenesis imaging in scleroderma to track digital ulcers
A patient-friendly look at using a special imaging tracer to watch blood vessel growth in the hands of people with scleroderma to help manage digital ulcers.
-
Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma
A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.
-
Pediatric Scleroderma: Mapping Cells and Tissues to Personalize Care
A study will map the different cell types and tissue patterns in skin from children with scleroderma to identify patient-specific disease subtypes that could guide targeted therapies.
-
CD38 and NAD metabolism in scleroderma (systemic sclerosis) fibrosis
This grant explores how changes in NAD metabolism related to CD38 and NNMT may drive scarring in systemic sclerosis and tests new ways to stop it.
-
ISG15-positive monocytes and SPP1 macrophages in scleroderma lung disease
This grant studies a specific immune cell pathway in systemic sclerosis with lung scarring to help predict how the disease progresses.
-
Autoantibodies define scleroderma subgroups with distinct cancer links
Researchers are studying how specific autoantibodies in scleroderma patients relate to cancer timing and risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.